

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4715809

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PAD PHARMA LIMITED	03/02/2016
RECEIVING PARTY DATA	
Name:	MICROSENS BIOPHAGE LTD
Street Address:	2 ROYAL COLLEGE STREET
City:	LONDON
State/Country:	UNITED KINGDOM
Postal Code:	NW1 0NH
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	8383617
CORRESPONDENCE DATA	
Fax Number:	(703)770-7901
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	703-770-7900
Email:	maggie.barham@pillsburylaw.com
Correspondent Name:	PILLSBURY WINTHROP SHAW PITTMAN, LLP
Address Line 1:	P.O. BOX 10500
Address Line 4:	MCLEAN, VIRGINIA 22102
ATTORNEY DOCKET NUMBER:	011765-0381885
NAME OF SUBMITTER:	MARGARET BARHAM
SIGNATURE:	/Margaret Barham/
DATE SIGNED:	12/04/2017
Total Attachments: 2	
source=Assignment#page1.tif	
source=Assignment#page2.tif	

PAD Pharma Ltd
2 Royal College Street
London
NW1 0NH

To: Microsens Biophage Ltd
2 Royal College Street
London
NW1 0NH


March 2nd 2016

Dear Sirs

Assignment of US 8,383,617 to Microsens Biophage Ltd.

The assignment agreement is attached.

Yours sincerely

A handwritten signature in black ink, appearing to read 'S.W.', with a horizontal line extending to the right.

Dr Stuart Wilson
Director

This Patent Assignment Agreement is made on March 2nd 2016 (the "Effective Date") between PAD Pharma Ltd with its principal place of business at 2 Royal College Street London NW1 0NH (the "Assignor")

and

Microsens Biophage Ltd with its principal place of business at 2 Royal College Street London NW1 0NH (the "Assignee").

RECITALS:

A. The Assignor is the owner of an issued patent, which the Assignor has agreed to assign to the Assignee.

The parties agree as follows:

B. Assignment. The Assignor hereby absolutely, irrevocably, and unconditionally assigns to the Assignee its entire interest in U.S. Patent Number US 8,383,617 dated February 26th 2013, previously published as US 2010/003589A1, titled Treatment of Protein Aggregation Diseases, claiming priority from GB 0701970.6 and GB 0704106.6, for the entire remaining term of the Patent and any domestic reissues or extensions of its term.

C. Ownership of Patent. The Assignor warrants to the Assignee that it is the sole owner of the Patent. It is under no restriction or obligation that may affect its right to assign the Patent.

D. Further Assurances. The Assignor shall sign (or cause to be signed) all further documents, do (or cause to be done) all further acts, and provide all assurances as may reasonably be necessary or desirable to give effect to the terms of this agreement.

Governing Law. The laws of England and Wales shall govern this assignment.

Effective Date. This agreement is effective as of the Effective Date.

This agreement has been signed by the parties.

PAD Pharma Ltd

By: 

Name: SM Wilson

Title: Director

Date: March 2nd 2016

Microsens Biophage Ltd

By: 

Name: SM Wilson

Title: Director

Date: March 2nd 2016

PAD Pharma Ltd